Citi raised the firm’s price target on Ardelyx to $12 from $10 and keeps a Buy rating on the shares. The firm says Xphozah delivered an “exceptional” Q2 with $37.1M in sales, handily beating consensus of $20.2M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
- Ardelyx announces publication of two plain language summaries from XPHOZAH
- Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
- ARDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ardelyx lawsuit unlikely to succeed, says H.C. Wainwright